Interactive Features

Test Your Knowledge

Quiz: Which Approach Offers Improved Safety with J591 for mCRPC?

07/29/2021

Which treatment approach demonstrates greater safety outcomes when using a full-length antibody to target PSMA, particularly with actinium J591, for patients with mCRPC?

Which treatment approach...

07/29/2021

Oncology

Test Your Knowledge

Quiz: Which Therapy Provides Targeted Radiation Delivery for PSMA-Expressive mCRPC?

07/29/2021

Which type of therapy for PSMA-expressive mCRPC supports targeted radiation delivery to tumors and prevents excessive damage to normal tissue?

Which type of therapy for...

07/29/2021

Oncology

Test Your Knowledge

Quiz: Somatic Sequencing in Metastatic Prostate Cancer

07/28/2021

True or False: Somatic sequencing of metastatic tissue in prostate cancer is challenging due to the bone‑trophic nature of advanced prostate cancer, as well as the diagnostic yield from sequencing bone metastases being quite low.

True or False: Somatic...

07/28/2021

Oncology

Test Your Knowledge

Quiz: What Data Led to the Rucaparib Approval for BRCAmut+ mCRPC Treatment?

06/01/2021

True or False: Rucaparib was approved for treatment of BRCAmut+ mCRPC based on response rate and patient response duration.

True or False: Rucaparib was...

06/01/2021

Oncology

Test Your Knowledge

Quiz: Rucaparib Treatment in BRCAmut+ mCRPC

06/01/2021

True or False: 10% of men were taken off rucaparib treatment entirely by their doctors due to side effects; however, the reason was different for each patient.

True or False: 10% of men were...

06/01/2021

Oncology

Test Your Knowledge

Quiz: Can You Identify the Two Types of BRCA Gene Mutations?

06/01/2021

What are the two types of BRCA gene mutations?

What are the two types of BRCA...

06/01/2021

Oncology

Test Your Knowledge

Quiz: The Role of BRCA Status in Prostate Cancer Treatment

06/01/2021

True or False: BRCA gene mutations increase the likelihood of developing certain cancers, including prostate cancer, and may help your doctor anticipate the aggressiveness of your disease and evaluate treatment options.

True or False: BRCA gene...

06/01/2021

Oncology

Test Your Knowledge

Quiz: Does Adding Hormone Therapy Extend Survival in Prostate Cancer?

06/27/2019

True or false: Salvage radiotherapy combined with short-term hormone therapy significantly improved metastatic-free survival compared with salvage radiotherapy alone in patients who underwent prostatectomies.

True or false: Salvage...

06/27/2019

Oncology

Test Your Knowledge

Quiz: Does Carbon Ion Radiotherapy Reduce Subsequent Primary Cancer Risk in Prostate Cancer?

04/10/2019

True or false: Carbon ion radiotherapy has been shown to reduce the risk for subsequent primary cancers in patients with localized prostate cancer.

True or false: Carbon ion...

04/10/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology